
SNOMED CT New Zealand Extension PRODUCTION Release Notes - April 2022



© 2024 International Health Terminology Standards Development Organisation. All rights reserved. SNOMED CT® was originally created by the College of American Pathologists.

This document forms part of the SNOMED CT® New Zealand Extension release distributed by International Health Terminology Standards Development Organisation, trading as SNOMED International, and is subject to the SNOMED CT® Affiliate License, details of which may be found at ht tps://www.snomed.org/snomed-ct/get-snomed

No part of this document may be reproduced or transmitted in any form or by any means, or stored in any kind of retrieval system, except by an Affiliate of SNOMED International in accordance with the SNOMED CT® Affiliate License. Any modification of this document (including without limitation the removal or modification of this notice) is prohibited without the express written permission of SNOMED International.

Any copy of this document that is not obtained directly from SNOMED International [or a Member of SNOMED International] is not controlled by SNOMED International, and may have been modified and may be out of date. Any recipient of this document who has received it by other means is encouraged to obtain a copy directly from SNOMED International [or a Member of SNOMED International. Details of the Members of SNOMED International may be found at https://www.snomed.org/members/].



Page At A Glance

- Introduction
- Background
- Content development activity
 - Summary
 - New and updated content
 - Concept statistics
 - Description
 - statistics
 Reference
 - sets
 Language reference
 - setsMaps
- Technical notes
 - Known Issues
 - Notice of changes to the International Edition Release Schedule
- Appendix 1

Introduction



The Ministry of Health works with health and disability agencies and their industry partners to develop SNOMED CT® reference sets, maps, language reference sets and other content for digital health solutions in Aotearoa New Zealand.

The SNOMED CT New Zealand Extension packages these components for release every April and October, to be used with the latest designated SNOMED CT International Edition release.

The same content can be viewed online using the SNOMED CT browser and accessed via our standard SNOMED CT terminology service.

We welcome your feedback and participation. For more information about SNOMED CT implementation in New Zealand, see our website or join our standards channel at forum.hinz.org.nz.

Background

This document provides a summarized description of the content changes included in the April 2022 production release of the SNOMED NZ Extension package.

It will also include technical notes detailing any known issues which have been identified. These are content or technical issues where the root cause is understood, and the fix has been discussed and agreed, but has yet to be implemented.

This SNOMED NZ Extension package is dependent upon, and should therefore be consumed in conjunction with the SNOMED CT January 2022 International Edition release.

Content development activity

Summary

Content from the SNOMED CT January 2022 International Edition release has been incremented, using additional components for use in New Zealand

The April 2022 release includes updates to the previously released content in the SNOMED CT NZ Extension release and introduces some new content.

New and updated content

Concept statistics

The SNOMED NZ National Release Centre promoted 5 new concepts into the SNOMED CT January 2022 International Edition release.

Table 1. New concepts in the SNOMED International January 2022 release by hierarchy

Total number of concepts	5
Qualifier value (qualifier value)	5

Refer to Appendix 1, Table 1.1 to view the 5 new concepts.

There are 213 new concepts in this release.

Table 2. New concepts in the SNOMED NZ Extension April 2022 release by hierarchy

Total number of concepts	213
Clinical finding (finding)	24
Procedure (procedure)	154
Qualifier value (qualifier value)	2
Situation with explicit context (situation)	30
SNOMED CT Model Component (metadata)	2
Social context (social concept)	1

Refer to Appendix 1, Table 2.1 to view the 213 new concepts.

Description statistics

The SNOMED NZ NRC promoted 1 new descriptions to the SNOMED International Edition January 2022 release.

Table 3. New descriptions in the SNOMED International January 2022 release

SNOMED CT Concept ID (SCTID)	SNOMED CT Fully Specified Name (FSN)	New description
2451000175103	Perinatology service (qualifier value)	Maternal fetal medicine service

There are 56 new descriptions in this release.

Table 4 New descriptions in the SNOMED NZ Extension April 2022 release

SNOMED CT Concept ID (SCTID)	SNOMED CT Fully Specified Name (FSN)	New description
171417004	Pre-school child health examination (procedure)	Before school check
472825005	Fetal chromosomal abnormality screening (procedure)	Fetal anomaly screening
445903002	Insertion of cardiac monitoring implant using fluoroscopic guidance (procedure)	Insertion of a pacemaker reveal monitor using fluoroscopic guidance
1163003002	Colorectal cancer screening service (qualifier value)	NZ bowel screening programme
14926007	pM1 category (finding)	pM1
443841006	pM1a category (finding)	pM1c
443840007	pM1b category (finding)	pM1a
443839005	pM1c category (finding)	pM1c
21917009	pN0 category (finding)	pN0
443335006	pN0(i-) category (finding)	pN0(i-)
443486002	pN0(i+) category (finding)	pN0(i+)
443963003	pN0(mol-) category (finding)	pN0(mol-)
443875007	pN0(mol+) category (finding)	pN0(mol+)
45552005	pN1 category (finding)	pN1
443716008	pN1a category (finding)	pN1a
443599002	pN1b category (finding)	pN1b
443743003	pN1c category (finding)	pN1c
443824009	pN1mi category (finding)	pN1mi
15076001	pN2 category (finding)	pN2
443867001	pN2a category (finding)	pN2a
443452006	pN2b category (finding)	pN2b
443893008	pN2c category (finding)	pN2c
49182004	pN3 category (finding)	pN3
443866005	pN3a category (finding)	pN3a

443962008	pN3b category (finding)	pN3b
443823003	pN3c category (finding)	pN3c
80663004	pN4 category (finding)	pN4
54452005	pNX category (finding)	pNX
39880006	pT0 category (finding)	рТО
53786006	pT1 category (finding)	pT1
443357004	pT1a category (finding)	pT1a
444432000	pT1a1 category (finding)	pT1a1
444439009	pT1a2 category (finding)	pT1a2
443506002	pT1b category (finding)	pT1b
444417007	pT1b1 category (finding)	pT1b1
444440006	pT1b2 category (finding)	pT1b2
443642002	pT1c category (finding)	pT1c
443600004	pT1mic category (finding)	pT1mi
80898003	pT2 category (finding)	pT2
443812002	pT2a category (finding)	pT2a
443896000	pT2b category (finding)	pT2b
443956003	pT2c category (finding)	pT2c
90402004	pT3 category (finding)	рТЗ
443606005	pT3a category (finding)	рТЗа
443815000	pT3a,b category (finding)	pT3a,b
443817008	pT3b category (finding)	pT3b
443674009	pT3c category (finding)	pT3c
443784000	pT3c,d category (finding)	pT3c,d
443479005	pT3d category (finding)	pT3d
6123003	pT4 category (finding)	pT4
443604008	pT4a category (finding)	pT4a
443736009	pT4b category (finding)	pT4b
443721006	pT4c category (finding)	pT4c
443505003	pT4d category (finding)	pT4d
84921008	pTis category (finding)	pTis
43189003	pTX category (finding)	pTX

Reference sets

There are 57 reference sets in the April 2022 release.

For more information about New Zealand reference sets, please visit our website.

The New Zealand reference set list is available in Appendix 1, table 3.1.

Language reference sets

Language reference sets are created to define preferred terms and synonyms associated with each concept. There are three language reference sets in the April 2022 release.

Language Reference Set Name	SNOMED CT Concept ID (SCTID)	Members
Maori [International Organization for Standardization 639-1 code mi] language reference set (foundation metadata concept)	291000210106	157
New Zealand English language reference set (foundation metadata concept)	271000210107	1155061
New Zealand English patient friendly terms language reference set (foundation metadata concept)	281000210109	157

Maps

Five maps between SNOMED CT and other code systems are contained in the April 2022 release.

Map Name	SNOMED CT Concept ID (SCTID)	Members
ACC translation table map (foundation metadata concept)	401000210101	12795
MSD translation table map (foundation metadata concept)	411000210104	58134
NZMT medicinal product to SNOMED CT map (foundation metadata concept)	311000210107	2125
READ v2 to SNOMED CT map (foundation metadata concept)	31000210106	88273
SNOMED CT to READ v2 map (foundation metadata concept)	41000210103	66966

Technical notes

Known Issues

Known Issues are content or technical issues where the root cause is understood, and the resolution has been discussed and agreed but has yet to be implemented. This can be due to a number of reasons, from lack of capacity within the current editing cycle, to the risk of impact to the stability of SNOMED CT if the fix were to be deployed at that stage in the Product lifecycle.

The following known issues were identified, and agreed to be resolved in the next editing cycle:

Notice of changes to the International Edition Release Schedule

As you may already know SNOMED International are transitioning to a monthly delivery schedule for the International Edition of SNOMED CT. The move towards more frequent releases of SNOMED CT will realize several benefits, including:

- The potential to be able to get content changes into the terminology in a shorter time frame.
- The fostering of better interoperability, as a result of entities being able to consume release content that is more aligned with other organizations.
- The prevention of circular dependencies that occur in longer projects, due to the move towards smaller, more manageable authoring projects.
- · More automated validation services, as a result of the inherent removal of the Alpha/Beta stages in the Release cycle.

Whilst most users will continue unaffected (as they can simply continue to download the releases every 6 months as always), this transition will necessarily involve a few changes to process/packages:

- Delta files have been removed from both International and Managed Service release packages, including the New Zealand
 Extension. A Delta Generation service will be provided for those who need it. The Delta Generation Tool allows users to create their
 own Delta between two fixed release dates you can find it here:
 - https://github.com/IHTSDO/delta-generator-tool/releases
- The ICD-O/ICD-10 Maps will continue to be published in each Monthly International Edition release package (in line with that month's
 content) for the foreseeable future, unless we experience issues with the new process in Production, and they need to be removed at a
 later date.

The first monthly Release of the SNOMED CT International Edition was published on the 28th February 2022 with the Delta files having been removed, and therefore they will be removed from the New Zealand Extension from the April 2022 Release onwards.

Please note - While the SNOMED CT International Edition is moving to monthly releases, the New Zealand Extension of SNOMED CT will remain on the current bi-annual release schedule of April and October for 2022.

Appendix 1

Table 1.1. New concepts in SNOMED CT International Edition January 2022 release

SNOMED CT Concept ID (SCTID)	SNOMED CT Fully Specified Name (FSN)	Semantic tag
1163003002	Colorectal cancer screening service (qualifier value)	Qualifier value
1163004008	Hyperbaric medicine service (qualifier value)	Qualifier value
1163002007	Electrocardiography service (qualifier value)	Qualifier value
11364210001681 09	Sleep medicine service (qualifier value)	Qualifier value
1163054002	Gastroscopy service (qualifier value)	Qualifier value

Table 2.1. New concepts in the SNOMED NZ Extension April 2022 release

SNOMED CT Concept ID (SCTID)	SNOMED CT Fully Specified Name (FSN)	Semantic tag
814610002101 03	Ring tight on digit of foot (disorder)	Disorder
814510002101 01	Ring tight on digit of hand (disorder)	Disorder
916310002101 08	Analgesics not given (finding)	Finding
101561000210 107	Cesarean section assessment (finding)	Finding
917710002101 02	Cesarean section category 1 - immediately life treatening to the woman or fetus (finding)	Finding
101531000210 103	Cesarean section category 2 - woman or fetus compromised not immediately life treatening (finding)	Finding
101541000210 106	Cesarean section category 3 - decision for earlier delivery made by health service (finding)	Finding
101551000210 109	Cesarean section category 4 - decision for rescheduled delivery made by health service and woman (finding)	Finding
101481000210 100	Fully breastfed (finding)	Finding
915710002101 09	In transit birth (finding)	Finding
101601000210 107	Infant artificially fed (finding)	Finding
916710002101 05	Newborn hearing screening failure referred to specialist (finding)	Finding
916510002101 02	Newborn hearing screening passed (finding)	Finding
916610002101 04	Newborn hearing screening passed surveillance required (finding)	Finding
916410002101 00	Newborn hearing screening status (finding)	Finding
101641000210 105	Partially breastfed (finding)	Finding
915410002101 04	Primary facility birth (finding)	Finding
915510002101 01	Secondary facility birth (finding)	Finding
916010002101 03	Stopped drinking alcohol before pregnancy (finding)	Finding
101491000210 103	Stopped drinking alcohol during first trimester of pregnancy (finding)	Finding
916110002101 01	Stopped drinking alcohol during pregnancy (finding)	Finding
101501000210 108	Stopped drinking alcohol during second trimester of pregnancy (finding)	Finding

101511000210 105	Stopped drinking alcohol during third trimester of pregnancy (finding)	Finding
915610002101 03	Tertiary facility birth (finding)	Finding
121531000210 107	New Zealand radiology procedures reference set (foundation metadata concept)	Foundation metadata concept
121521000210 105	New Zealand severe acute respiratory syndrome coronavirus 2 symptoms reference set (foundation metadata concept)	Foundation metadata concept
814810002101 06	Rural hospital medicine specialist (occupation)	Occupation
121541000210 104	Aspiration and/or drainage of back region using computed tomography guidance (procedure)	Procedure
121551000210 101	Aspiration and/or drainage of neck using computed tomography guidance (procedure)	Procedure
111521000210 103	Combined first trimester maternal serum and nuchal translucency scan (procedure)	Procedure
131511000210 102	Diagnostic radiography of temporomandibular joint and orthopantogram (procedure)	Procedure
101711000210 104	Gateway assessment (procedure)	Procedure
101621000210 104	Induction of labor by artificial rupture of membranes and using oxytocin (procedure)	Procedure
121511000210 100	Non-invasive Prenatal Screening (procedure)	Procedure
101581000210 104	Non-opioid analgesic therapy (procedure)	Procedure
111481000210 103	Non-pharmacological pain management therapy (procedure)	Procedure
101661000210 106	Opioid analgesic therapy (procedure)	Procedure
101721000210 109	Referral for Gateway assessment (procedure)	Procedure
111531000210 101	Second trimester maternal serum screening (procedure)	Procedure
915110002101 00	X-ray of chest, cervical spine and pelvis (procedure)	Procedure
915810002101 06	Pacific health service (qualifier value)	Qualifier value
915910002101 08	Plunket service (qualifier value)	Qualifier value
584810002101 05	Breast metastatic Abraxane-paclitaxel nanoparticle albumin bound and atexolizumab chemotherapy regimen (regime/therapy)	Regime/therapy
586010002101 03	Breast metastatic carboplatin and gemcitabine chemotherapy regimen (regime/therapy)	Regime/therapy
577910002101 02	Breast metastatic carboplatin chemotherapy regimen (regime/therapy)	Regime/therapy
585310002101 07	Breast metastatic denosumab chemotherapy regimen (regime/therapy)	Regime/therapy
586410002101 00	Breast metastatic doxorubicin every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy

586110002101 01	Breast metastatic doxorubicin weekly chemotherapy regimen (regime/therapy)	Regime/therapy
577810002101 04	Breast metastatic epirubicin and cyclophosphamide chemotherapy regimen (regime/therapy)	Regime/therapy
586310002101 08	Breast metastatic eribulin chemotherapy regimen (regime/therapy)	Regime/therapy
584910002101 07	Breast metastatic everolimus and exemestane chemotherapy regimen (regime/therapy)	Regime/therapy
585410002101 04	Breast metastatic fulvestrant chemotherapy regimen (regime/therapy)	Regime/therapy
585910002101 08	Breast metastatic gemcitabine chemotherapy regimen (regime/therapy)	Regime/therapy
578010002101 03	Breast metastatic goserelin every four weeks chemotherapy regimen (regime/therapy)	Regime/therapy
585610002101 03	Breast metastatic goserelin every twelve weeks chemotherapy regimen (regime/therapy)	Regime/therapy
585110002101 00	Breast metastatic Kadcyla- trastuzumab emtansine chemotherapy regimen (regime/therapy)	Regime/therapy
585210002101 05	Breast metastatic mitomycin, mitoxantrone and methotrexate chemotherapy regimen (regime/therapy)	Regime/therapy
585810002101 06	Breast metastatic paclitaxel weekly and trastuzumab every three weeks chemotherapy regimen (regime /therapy)	Regime/therapy
585010002101 02	Breast metastatic paclitaxel weekly chemotherapy regimen (regime/therapy)	Regime/therapy
586210002101 06	Breast metastatic paclitaxel weekly, pertuzmab and trastuzumab every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy
578110002101 01	Breast metastatic palbociclib chemotherapy regimen (regime/therapy)	Regime/therapy
585710002101 09	Breast metastatic pamidronate chemotherapy regimen (regime/therapy)	Regime/therapy
585510002101 01	Breast metastatic pembrolizumab every three weeks flat dosing (regime/therapy)	Regime/therapy
584610002101 02	Breast metastatic trastuzumab every three weeks and vinorelbine intravenous chemotherapy regimen (regime/therapy)	Regime/therapy
584710002101 08	Breast metastatic trastuzumab every three weeks and vinorelbine oral chemotherapy regimen (regime /therapy)	Regime/therapy
586510002101 02	Breast metastatic trastuzumab every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy
578310002101 08	Breast metastatic trastuzumab subcutaneous chemotherapy regimen (regime/therapy)	Regime/therapy
578210002101 06	Breast metastatic vinorelbine intravenous chemotherapy regimen (regime/therapy)	Regime/therapy
577710002101 01	Breast metastatic vinorelbine intravenous weekly chemotherapy regimen (regime/therapy)	Regime/therapy
577610002101 07	Breast non-metastatic AC doxorubicin and cyclophosphamide dose dense chemotherapy regimen (regime /therapy)	Regime/therapy
578410002101 00	Breast non-metastatic doxorubicin and cyclophosphamide every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy
578510002101 02	Breast non-metastatic paclitaxel weekly pertuzumab and trastuzumab every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy
527910002101 00	Colorectal rectal metastatic capecitabine chemoradiation continuous dosing chemotherapy regimen (regime/therapy)	Regime/therapy

131531000210 109	Growth factor prophylaxis not recommended (situation)	Regime/therapy
526910002101 06	Respiratory mesothelioma metastatic carboplatin and pemetrexed chemotherapy regimen (regime/therapy)	Regime/therapy
527110002101 08	Respiratory mesothelioma metastatic cisplatin and pemetrexed chemotherapy regimen (regime/therapy)	Regime/therapy
528310002101 06	Respiratory non small cell lung cancer metastatic carboplatin and docetaxel chemotherapy regimen (regime/therapy)	Regime/therapy
528210002101 09	Respiratory non small cell lung cancer metastatic carboplatin and pemetrexed chemotherapy regimen (regime/therapy)	Regime/therapy
528110002101 04	Respiratory non small cell lung cancer metastatic docetaxel every three weeks chemotherapy regimen (regime/therapy)	Regime/therapy
528010002101 01	Respiratory non small cell lung cancer metastatic docetaxel weekly (regime/therapy)	Regime/therapy
526810002101 09	Respiratory non small cell lung cancer metastatic paclitaxel weekly (regime/therapy)	Regime/therapy
527210002101 03	Respiratory non small cell lung cancer metastic afatinib chemotherapy regimen (regime/therapy)	Regime/therapy
527310002101 01	Respiratory non small cell lung cancer metastic atezolizumab chemotherapy regimen (regime/therapy)	Regime/therapy
527410002101 09	Respiratory non small cell lung cancer metastic dabrafenib and trametinib chemotherapy regimen (regime /therapy)	Regime/therapy
527010002101 06	Respiratory non small cell lung cancer metastic nivolumab biweekly chemotherapy regimen (regime /therapy)	Regime/therapy
527510002101 07	Respiratory non small cell lung cancer metastic nivolumab biweekly weight base dosing chemotherapy regimen (regime/therapy)	Regime/therapy
527610002101 05	Respiratory non small cell lung cancer metastic nivolumab every four weeks flat dosing chemotherapy regimen (regime/therapy)	Regime/therapy
528510002101 00	Respiratory non small cell lung cancer non-metastatic cisplatin and etoposide chemoradiation chemotherapy regimen (regime/therapy)	Regime/therapy
528610002101 02	Respiratory non small cell lung cancer non-metastatic crizotinib chemotherapy regimen (regime/therapy)	Regime/therapy
527810002101 02	Respiratory non small cell lung cancer non-metastatic durvalumab chemotherapy regimen (regime/therapy)	Regime/therapy
528410002101 03	Respiratory non small cell lung cancer non-metastatic superior sulcus pancoast cisplatin and etoposide chemoradiation chemotherapy regimen (regime/therapy)	Regime/therapy
527710002101 04	Respiratory non small cell lung cancer non-metastic atezolizumab chemotherapy regimen (regime/therapy)	Regime/therapy
573710002101 02	Respiratory small cell lung cancer metastatic CAV extensive cyclophoshamide 750, doxorubicin and vincristine chemotherapy regimen (regime/therapy)	Regime/therapy
528710002101 08	Respiratory small cell lung cancer metastatic CAV extensive cyclophosphamide 1000, doxorubicin and vincristine chemotherapy regimen (regime/therapy)	Regime/therapy
573810002101 00	Respiratory small cell lung cancer non-metastatic Limited carboplatin and etoposide chemotherapy regimen (regime/therapy)	Regime/therapy
573910002101 03	Respiratory small cell lung cancer non-metastatic Limited cisplatin and etoposide chemotherapy regimen (regime/therapy)	Regime/therapy
574410002101 02	Skin cancer basal cell metastatic vismodegib chemotherapy regimen (regime/therapy)	Regime/therapy
574610002101 01	Skin cancer melanoma metastatic - cobimetinib and vemurafenib chemotherapy regimen (regime/therapy)	Regime/therapy
574710002101 07	Skin cancer melanoma metastatic - dacarbazine chemotherapy regimen (regime/therapy)	Regime/therapy

574810002101 Skin cancer melanoma metastatic - imatinib chemotherapy regimen (regime/therapy) Regime/th 574910002101 Skin cancer melanoma metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg chemotherapy regimen Regime/th 575010002101 Skin cancer melanoma metastatic - ipilimumab 3mg/kg and nivolumab 1mg/kg chemotherapy regimen Regime/th 575110002101 Skin cancer melanoma metastatic - ipilimumab and pembrolizumab chemotherapy regimen (regime Regime/th 575410002101 Skin cancer melanoma metastatic - nivolumab every four weeks flat dosing chemotherapy regimen (regime Regime/th 575210002101 Skin cancer melanoma metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Regime/th 575310002101 Skin cancer melanoma metastatic - pembrolizumab every two weeks weight based dosing chemotherapy regimen Regime/th 575510002101 Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen Regime/th 575510002101 Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th 575610002101 Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Regime/th 575810002101 Skin cancer melanoma non-metastatic - nivolumab eve
06 (regime/therapy) Regime/th 575010002101 Skin cancer melanoma metastatic - ipilimumab 3mg/kg and nivolumab 1mg/kg chemotherapy regimen (regime / therapy) Regime/th 575110002101 Skin cancer melanoma metastatic - ipilimumab and pembrolizumab chemotherapy regimen (regime / therapy) Regime/th 575210002101 Skin cancer melanoma metastatic - nivolumab every four weeks flat dosing chemotherapy regimen (regime / therapy) Regime/th 575210002101 Skin cancer melanoma metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime / therapy) Regime/th 575310002101 Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Regime/th 575510002101 Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Regime/th 575610002101 Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th 574010002101 Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th 574510002101 Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Regime/th 575810002101 Skin cancer melanoma non-metastatic - nivolu
(regime/therapy) Regime/therapy Skin cancer melanoma metastatic - ipilimumab and pembrolizumab chemotherapy regimen (regime /therapy) Skin cancer melanoma metastatic - nivolumab every four weeks flat dosing chemotherapy regimen (regime /therapy) Skin cancer melanoma metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime /therapy) Regime/th/therapy) Skin cancer melanoma metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Regime/th/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy Regime/th/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy Regime/th/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy Regime/th/th/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy Regime/th/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy Regime/th/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing Regime/th/therapy) Skin can
755410002101 Skin cancer melanoma metastatic - nivolumab every four weeks flat dosing chemotherapy regimen (regime /therapy) Skin cancer melanoma metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime /therapy) Skin cancer melanoma metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
7/therapy) Skin cancer melanoma metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th (regime/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing Regime/th chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing Regime/th chemotherapy regimen (regime/therapy)
757510002101 Skin cancer melanoma metastatic - pembrolizumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th (regime/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy Regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy Regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing Regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing Regime/therapy)
regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Regime/th Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
(regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Regime/th Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
(regime/therapy) Skin cancer melanoma metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
regimen (regime/therapy) Skin cancer melanoma metastatic binimetinib and encorafenib chemotherapy regimen (regime/therapy) Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy Regime/th regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
574510002101 Skin cancer melanoma metastatic carboplatin, paclitaxel, and bevacizumab chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
(regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
05 (regime/therapy) 575910002101 Skin cancer melanoma non-metastatic - nivolumab every two weeks weight based dosing chemotherapy of regimen (regime/therapy) 576110002101 Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) 576210002101 Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) 576010002101 Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/the
regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
00 regimen (regime/therapy) 576210002101 Skin cancer melanoma non-metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy) 576010002101 Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
 chemotherapy regimen (regime/therapy) Skin cancer melanoma non-metastatic nivolumab every four weeks flat dosing chemotherapy regimen Regime/th
576310002101 Skin cancer melanoma non-metastatic pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy)
574110002101 Skin cancer merkel cell metastatic pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy)
574310002101 Skin cancer Merkel cell metastatic pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy)
574210002101 Skin cancer Merkel cell metastatic pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
576410002101 Skin cancer squamous cell metastatic - pembrolizumab every three weeks flat dosing chemotherapy regimen (regime/therapy)
576510002101 Skin cancer squamous cell metastatic - pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)
576610002101 Skin cancer squamous cell metastatic pembrolizumab every six weeks flat dosing chemotherapy regimen (regime/therapy)
542310002101 Upper gastrointestinal biliary and gallbladder Metastatic carboplatin and gemcitabine chemotherapy regimen (regime/therapy)
542210002101 Upper gastrointestinal biliary and gallbladder metastatic gemcitabine chemotherapy regimen (regime /therapy)

541510002101 04	Upper gastrointestinal biliary and gallbladder metastatic modified fluorouracil, folinic acid and oxaliplatin high dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
542110002101 05	Upper gastrointestinal biliary and gallbladder metastatic modified fluorouracil, folinic acid and oxaliplatin low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
541910002101 06	Upper gastrointestinal biliary and gallbladder non-metastatic capecitabine chemotherapy regimen (regime /therapy)			
541810002101 09	Upper gastrointestinal biliary and gallbladder non-metastatic modified fluorouracil, folinic acid and oxaliplatin low dose folinic acid chemotherapy regimen (regime/therapy)			
572810002101 08	Upper gastrointestinal biliary and gallbladder non-netastatic - modified fluorouracil, folinic acid and oxaliplatin high dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
540610002101 02	Upper gastrointestinal gastric and oesophageal metastatic - modified fluorouracil, folinic acid and irinotecan low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
540810002101 05	Upper gastrointestinal gastric and oesophageal metastatic - modified fluorouracil, folinic acid and oxaliplatin high dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
539710002101 06	Upper gastrointestinal gastric and oesophageal metastatic - modified oxaliplatin, folinic acid and fluorouracil low dose folinic acid and trastuzumab chemotherapy regimen (regime/therapy)	Regime/therapy		
530610002101 04	Upper gastrointestinal gastric and oesophageal metastatic capecitabine and oxaliplatin chemotherapy regimen (regime/therapy)	Regime/therapy		
529410002101 06	Upper gastrointestinal gastric and oesophageal metastatic capecitabine, oxaliplatin and trastuzumab chemotherapy regimen (regime/therapy)	Regime/therapy		
541210002101 08	Upper gastrointestinal gastric and oesophageal metastatic cisplatin and capecitabine chemotherapy regimen (regime/therapy)	Regime/therapy		
542510002101 09	Upper gastrointestinal gastric and oesophageal metastatic cisplatin and fluorouracil chemotherapy regimen (regime/therapy)			
572910002101 05	Upper gastrointestinal gastric and oesophageal metastatic cisplatin, capecitabine and trastuzumab chemotherapy regimen (regime/therapy)			
573010002101 09	Upper gastrointestinal gastric and oesophageal metastatic cisplatin, fluorouracil and trastuzumab chemotherapy regimen (regime/therapy)			
529210002101 00	Upper gastrointestinal gastric and oesophageal metastatic irinotecan every two weeks chemotherapy regimen (regime/therapy)			
529510002101 09	Upper gastrointestinal gastric and oesophageal metastatic modified fluorouracil, folinic acid and oxaliplatin high dose folinic acid and trastuzumab chemotherapy regimen (regime/therapy)	Regime/therapy		
530710002101 05	Upper gastrointestinal gastric and oesophageal metastatic modified fluorouracil, folinic acid, irinotecan high dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
528910002101 07	Upper gastrointestinal gastric and oesophageal metastatic modified fluorouracil, folinic acid, oxaliplatin low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
540910002101 07	Upper gastrointestinal gastric and oesophageal metastatic paclitaxel and ramucirumab chemotherapy regimen (regime/therapy)	Regime/therapy		
529110002101 05	Upper gastrointestinal gastric and oesophageal metastatic paclitaxel weekly 3/1 dosing chemotherapy regimen (regime/therapy)	Regime/therapy		
529010002101 08	Upper gastrointestinal gastric and oesophageal metastatic paclitaxel weekly chemotherapy regimen (regime/therapy)	Regime/therapy		
529710002101 01	Upper gastrointestinal gastric and oesophageal metastatic pembrolizumab every three weeks flat dose chemotherapy regimen (regime/therapy)	Regime/therapy		
541110002101 03	Upper gastrointestinal gastric and oesophageal metastatic pembrolizumab every three weeks weight based dosing chemotherapy regimen (regime/therapy)	Regime/therapy		
541010002101 00	Upper gastrointestinal gastric and oesophageal metastatic ramucirumab chemotherapy regimen (regime /therapy)	Regime/therapy		
542010002101 08	Upper gastrointestinal gastric and oesophageal metastatic trifluridine and tipiracil chemotherapy regimen (regime/therapy)	Regime/therapy		
530310002101	Upper gastrointestinal gastric and oesophageal non-metastatic docetaxel, oxaliplatin, folinic acid and	Regime/therapy		

530510002101 02	Upper gastrointestinal gastric and oesophageal non-metastatic docetaxel, oxaliplatin, folinic acid and fluorouracil low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
529310002101 03	Upper gastrointestinal gastric and oesophageal non-metastatic modified fluorouracil, folinic acid and oxaliplatin chemoradiation high dose folinic acid chemotherapy regimen (regime/therapy)			
529810002101 04	Upper gastrointestinal gastric and oesophageal non-metastic modified fluorouracil, folinic acid and oxaliplatin chemoradiation low dose folinic acid chemotherapy regimen (regime/therapy)			
573110002101 06	Upper gastrointestinal gastric metastatic cisplatin, capecitabine and pembrolizumab flat dose chemotherapy regimen (regime/therapy)			
529610002101 07	Upper gastrointestinal gastric non-metastatic capecitabine and oxaliplatin chemotherapy regimen (regime /therapy)	Regime/therapy		
540710002101 08	Upper gastrointestinal gastric non-metastatic fluorouracil chemoradiation modified MacDonald chemotherapy regimen (regime/therapy)	Regime/therapy		
530410002101 00	Upper gastrointestinal gastrointestinal stroma cell tumours metastatic imatinib chemotherapy regimen (regime/therapy)	Regime/therapy		
529910002101 02	Upper gastrointestinal gastrointestinal stromal cell tumors metastatic regorafenib chemotherapy regimen (regime/therapy)	Regime/therapy		
541610002101 01	Upper gastrointestinal gastrointestinal stromal cell tumour metastatic sunitinib 2/1 dosing chemotherapy regimen (regime/therapy)	Regime/therapy		
573210002101 01	Upper gastrointestinal gastrointestinal stromal cell tumours metastatic sunitinib 4/2 dosing chemotherapy regimen (regime/therapy)	Regime/therapy		
573310002101 04	Upper gastrointestinal gastrointestinal stromal cell tumours non-metastatic imatinib chemotherapy regimen (regime/therapy)	Regime/therapy		
573510002101 05	Upper gastrointestinal hepatic metastatic atezolizumab and bevacizumab chemotherapy regimen (regime /therapy)			
573410002101 07	Upper gastrointestinal hepatic metastatic atezolizumab chemotherapy regimen (regime/therapy)			
573610002101 08	Upper gastrointestinal hepatic metastatic lenvatinib chemotherapy regimen (regime/therapy)			
541310002101 05	Upper gastrointestinal hepatic metastatic sorafenib chemotherapy regimen (regime/therapy)	Regime/therapy		
528810002101 05	Upper gastrointestinal oesophageal non-metastatic carboplatin and paclitaxel weekly chemoradiation chemotherapy regimen (regime/therapy)	Regime/therapy		
542410002101 06	Upper gastrointestinal oesophageal non-metastatic cisplatin and fluorouracil chemoradiation chemotherapy regimen (regime/therapy)	Regime/therapy		
530010002101 03	Upper gastrointestinal oesophageal non-metastatic cisplatin and fluorouracil chemoradiation Herskovic chemotherapy regimen (regime/therapy)	Regime/therapy		
530110002101 01	Upper gastrointestinal oesophageal non-metastatic mitomycin and fluorouracil chemoradiation chemotherapy regimen (regime/therapy)	Regime/therapy		
530210002101 06	Upper gastrointestinal oesophageal non-metastatic mitomycin and fluorouracil chemoradiation MSKCC chemotherapy regimen (regime/therapy)	Regime/therapy		
577210002101 00	Upper gastrointestinal pancreas metastatic docetaxel, gemcitabine, cisplatin and capecitabine chemotherapy regimen (regime/therapy)	Regime/therapy		
541710002101 07	Upper gastrointestinal pancreas metastatic gemcitabine chemotherapy regimen (regime/therapy)	Regime/therapy		
572610002101 00	Upper gastrointestinal pancreas metastatic modified fluorouracil, folinic acid and oxaliplatin high dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
572710002101 06	Upper gastrointestinal pancreas metastatic modified fluorouracil, folinic acid and oxaliplatin low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy		
577010002101 08	Upper gastrointestinal pancreas metastatic olaparib chemotherapy regimen (regime/therapy)	Regime/therapy		
577410002101 06	Upper gastrointestinal pancreas non-metastatic capecitabine and gemcitabine adjuvant chemotherapy regimen (regime/therapy)	Regime/therapy		
		•		

577510002101 09	Upper gastrointestinal pancreas non-metastatic capecitabine and gemcitabine advanced chemotherapy regimen (regime/therapy)	Regime/therapy	
576710002101 09	Upper gastrointestinal pancreas non-metastatic capecitabine chemoradiation 5 day dosing chemotherapy regimen (regime/therapy)		
576810002101 06	Upper gastrointestinal Pancreas non-metastatic capecitabine chemoradiation continuous dosing chemotherapy regimen (regime/therapy)		
577110002101 05	Upper gastrointestinal pancreas non-metastatic gemcitabine adjuvant chemotherapy regimen (regime /therapy)	Regime/therapy	
576910002101 08	Upper gastrointestinal pancreas non-metastatic gemcitabine advanced chemotherapy regimen (regime /therapy)	Regime/therapy	
577310002101 03	Upper gastrointestinal pancreas non-metastatic oxaliplatin, irinotecan, folinic acid and fluorouracil low dose folinic acid chemotherapy regimen (regime/therapy)	Regime/therapy	
917210002101 01	Augmentation of labor not performed (situation)	Situation	
111511000210 108	Fetal anomaly screening declined (situation)	Situation	
914910002101 07	History of admission to neonatal intensive care unit (situation)	Situation	
915010002101 02	History of admission to special care baby unit (situation)	Situation	
111501000210 106	History of cervical intraepithelial neoplasia grade 3 (situation)	Situation	
917010002101 09	D10002101 History of cervical smear performed for more than three years (situation)		
121501000210 102	O210 History of cervical smear performed within last 12 months (situation)		
916910002101 09	O1 History of cervical smear performed within last three years (situation)		
916810002101 07	History of cervical smear performed within last two years (situation)	Situation	
101681000210 103	History of complementary therapy (situation)	Situation	
914610002101 02	History of complication in pregnancy (situation)	Situation	
916210002101 06	History of first trimester miscarriage (situation)	Situation	
915310002101 07	History of genital herpes simplex (situation)	Situation	
915210002101 05	History of genital warts (situation)	Situation	
101651000210 108	History of human immunodeficiency virus infection (situation)	Situation	
101591000210 102	History of non-opioid analgesic therapy (situation)	Situation	
111491000210 101	History of non-pharmacological pain management therapy (situation)	Situation	
101611000210 109	History of previous baby artificially fed (situation)	Situation	
917110002101 06	History of previous baby exclusively breastfed (situation)	Situation	
101471000210 102	History of previous baby fully breastfed (situation)	Situation	

121491000210 107	History of previous baby partially breast fed (situation)	Situation
101671000210 100	History of previous baby under pediatric care while in maternity unit (situation)	
131501000210 104	History of regional anesthesia (situation)	Situation
101521000210 100	Newborn hearing screening not done (situation)	Situation
101571000210 101	No history of administration of analgesic (situation)	Situation
914710002101 08	No history of neonatal care admission (situation)	Situation
917310002101 04	Primary facility birth planned (situation)	Situation
917410002101 07	Secondary facility birth planned (situation)	Situation
917510002101 05	Tertiary facility birth planned (situation)	Situation
101631000210 102	Vaccine product against Severe acute respiratory syndrome coronavirus 2 given (situation)	Situation

Table 3.1 Reference sets in the SNOMED NZ Extension April 2022 release

SNOMED CT SNOMED CT Fully Specified Name (FSN) Concept ID		Members
(SCTID)		
351000210106	New Zealand adverse reaction manifestation reference set (foundation metadata concept)	1886
72671000210109	New Zealand alcohol consumption reference set (foundation metadata concept)	3
421000210109	New Zealand ambulance clinical impression reference set (foundation metadata concept)	176
61241000210100	New Zealand biological substance common allergen reference set (foundation metadata concept)	208
91000210107	New Zealand cardiology reference set (foundation metadata concept)	63
61251000210102	New Zealand chemical substance common allergen reference set (foundation metadata concept)	623
191000210102	New Zealand child developmental services reference set (foundation metadata concept)	137
241000210102	New Zealand child health assessment reference set (foundation metadata concept)	186
471000210108	New Zealand clinical specialty reference set (foundation metadata concept)	158
61271000210105	New Zealand common pharmaceutical dose form reference set	12
61281000210107	New Zealand common pharmaceutical dose frequency reference set	12
61291000210109	New Zealand common pharmaceutical dose unit reference set	11
61231000210108	New Zealand COVID-19 adverse event from immunization reference set	58
261000210101	New Zealand disability reference set (foundation metadata concept)	96
61261000210104	New Zealand edible substance common allergen reference set	420
61000210102	New Zealand emergency care diagnosis reference set (foundation metadata concept)	1451
71000210108	New Zealand emergency care presenting complaint reference set (foundation metadata concept)	160
321000210102	New Zealand emergency care procedure reference set (foundation metadata concept)	73

141000210106	New Zealand endocrinology reference set (foundation metadata concept)	263		
181000210104	New Zealand general paediatric reference set (foundation metadata concept)			
131000210103	New Zealand general surgery reference set (foundation metadata concept)	97		
101000210108	New Zealand gynaecology reference set (foundation metadata concept)			
451000210100	New Zealand health occupation reference set (foundation metadata concept)			
461000210102	New Zealand health service type reference set (foundation metadata concept)			
501000210102	New Zealand laboratory order reference set (foundation metadata concept)			
72621000210105	New Zealand maternity Apgar score reference set (foundation metadata concept)	33		
72631000210107	New Zealand maternity complementary therapies reference set (foundation metadata concept)	17		
72601000210102	New Zealand maternity complications reference set (foundation metadata concept)	32		
72611000210100	New Zealand maternity disorders reference set (foundation metadata concept)	44		
72661000210103	New Zealand maternity family history reference set (foundation metadata concept)	12		
72591000210107	New Zealand maternity findings reference set (foundation metadata concept)	156		
72581000210105	New Zealand maternity mode of delivery reference set (foundation metadata concept)	4		
72571000210108	New Zealand maternity outcomes reference set (foundation metadata concept)	8		
72541000210103	New Zealand maternity previous complications reference set (foundation metadata concept)	47		
72551000210100	New Zealand maternity previous disorders reference set (foundation metadata concept)	63		
72531000210106 New Zealand maternity previous findings reference set (foundation metadata concept)				
72521000210109				
72511000210104 New Zealand maternity previous outcomes reference set (foundation metadata concept)				
New Zealand maternity previous procedures reference set (foundation metadata concept)				
72561000210102	New Zealand maternity procedures reference set (foundation metadata concept)	51		
72641000210104	New Zealand maternity screening and tests reference set (foundation metadata concept)	21		
72651000210101	New Zealand maternity substances reference set (foundation metadata concept)	13		
391000210104	New Zealand microorganism reference set (foundation metadata concept)	18718		
50931000210104	New Zealand nephrology reference set (foundation metadata)	99		
72691000210108	New Zealand non-medicinal drug reference set (foundation metadata concept)	16		
72681000210106	New Zealand non-medicinal drug use reference set (foundation metadata concept)	6		
251000210104	New Zealand notifiable disease reference set (foundation metadata concept)	96		
50941000210107	New Zealand ophthalmology reference set (foundation metadata concept)	64		
121531000210107	New Zealand radiology procedures reference set (foundation metadata concept)	915		
121000210100	New Zealand rheumatology reference set (foundation metadata concept)	126		
121521000210105	New Zealand severe acute respiratory syndrome coronavirus 2 symptoms reference set (foundation metadata concept)	19		
481000210105	New Zealand site of care reference set (foundation metadata concept)	8		
72731000210103	New Zealand smoking intervention reference set (foundation metadata concept)	5		
51000210100	New Zealand smoking reference set (foundation metadata concept)	42		
72741000210106	New Zealand smoking status reference set (foundation metadata concept)	4		
441000210103	New Zealand surgical complication reference set (foundation metadata concept)	147		
72721000210100	New Zealand vaping status reference set (foundation metadata concept)	7		

Approvals

Final Version	Date	Approver	Comments
0.1		Terance Shird	
0.2	22 Mar 2022	Lea Miharsa	Approved
1.0	22 Mar 2022	Alastair Kenworthy	Approved

Download .pdf here:

Draft Amendment History

Version	Date	Editor	Comments
0.1	01 Mar 2022	Andrew Atkinson	Initial draft created
0.2	22 Mar 2022	Lea Miharsa	Final draft
1.0	22 Mar 2022	Alastair Kenworthy	Final draft updated